Abstract 231P
Background
Body mass index (BMI) has shown the associated with clinical outcomes of immune checkpoint inhibitors (ICIs) treatment in patients with several malignancies. We previously reported the association between clinical outcome in advanced urothelial carcinoma (UC) patients treated with pembrolizumab and BMI according to the WHO international classification. However, no patient in our cohort was grouped into obese (BMI 30kg/m2≤) and WHO BMI classification may be unsuitable for Asians. Therefore, we investigated the association between BMI classification developed for Asian people and clinical outcomes of pembrolizumab for advanced UC.
Methods
We retrospectively reviewed consecutive patients with advanced UC who received pembrolizumab between December 2003 and March 2023. Patients were divided into three groups based on BMI classification for Asians; the non-overweight group (BMI < 22.9 kg/m2), the overweight group (23 ≤ BMI < 24.9 kg/m2), and the obese group (BMI ≥ 25 kg/m2). Tumor response, progression-free survival (PFS), overall survival (OS), and incidence of adverse events (AEs) were compared among the groups. We additionally investigated factors associated with PFS using the multivariate analysis.
Results
Of 99 eligible patients, 54 (54.5%), 21 (21.2%) and 24 (24.2%) were in the non-overweight, overweight and obese group, respectively. PFS was significantly longer in the obese group (median 10.3 months) than that in the non-overweight (median 4.2 months) and the overweight group (median 2.3 months) (p=0.04). Multivariate analysis showed that obese was significantly associated with favorable PFS. The obese group had higher objective response rate and longer OS compared to other groups, although the difference did not reach the statistical significance. Multivariate analysis showed that obese was significantly associated with favorable PFS. There was no difference in the occurrence of irAEs among three groups.
Conclusions
BMI was associated with PFS for patients with advanced UC received pembrolizumab and BMI Asian classification may be more useful and suitable for Asian patients than that of WHO classification.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract
78P - First-in-human phase I study of TT-00434, an orally available FGFR (1-3) inhibitor in patients with advanced solid tumors
Presenter: Chia Jui Yen
Session: Poster Display
Resources:
Abstract
79P - Accelerated identification of recurrent neoantigens for the development of off-the-shelf cancer vaccines
Presenter: Le Son Tran
Session: Poster Display
Resources:
Abstract
80P - Safety, preliminary efficacy, and pharmacokinetics of HLX26 plus serplulimab in advanced solid tumours: An open-label, dose-escalation phase I study
Presenter: Yanmin Wu
Session: Poster Display
Resources:
Abstract
81P - A first-in-human, multiple dose and dose escalation phase I study to investigate the safety, tolerability and antitumor activity of SmarT cells plus PD-1 blocking antibodies in patients with far advanced/metastatic solid tumors
Presenter: Qin Liu
Session: Poster Display
Resources:
Abstract
82P - NEXUS: A phase I dose escalation study of selinexor plus nivolumab and ipilimumab in Asian patients with advanced/metastatic solid malignancies
Presenter: Gloria Chan
Session: Poster Display
Resources:
Abstract
83P - The updated report of phase I trial of VG2025, a non-attenuated HSV-1 oncolytic virus expressing IL-12 and IL-15/RA payloads, in patients with advanced solid tumors
Presenter: Yinan Shen
Session: Poster Display
Resources:
Abstract
84P - T cell receptor repertoire profiles of tumor -infiltrating lymphocytes improves neoantigen prioritization for personalized cancer immunotherapy
Presenter: Tran Nguyen
Session: Poster Display
Resources:
Abstract
85P - Oligometastatic solid tumors: Disease characteristics and role of local therapies
Presenter: Alshimaa Al Hanafy
Session: Poster Display
Resources:
Abstract
86P - Efficacy and safety of HLX07 monotherapy in advanced cutaneous squamous cell carcinoma: An open-label, multicentre phase II study
Presenter: Changxing Li
Session: Poster Display
Resources:
Abstract